A GGD study into the HIV inhibitor PrEP showed that the treatment is an effective way to prevent an HIV infection, despite one of the 376 participants in the study contracting the virus, according to the Parool. PrEP, short for Pre-exposure prophylaxis, t is a way for people who do not have HIV, but who are at a high risk of getting the virus, to help prevent HIV infection by taking a pill every day. The pill, marketed under the brand name Truvada, contains the medicines tenofovir and emtricitabine, that are used in combination with other medications.
The number of new HIV diagnoses in the Netherlands decreased from 941 in 2015 to 664 last year, according to the latest figures from HIV monitoring foundation SHM. Two thirds of new HIV infections were diagnosed in men who have sex with other men. While most of these men were diagnosed at an early stage, a third was still only diagnosed after the virus already affected their immune system.
On Monday Amsterdam is starting with the national PrEP program, a nationwide experiment in which the HIV prevention pill is prescribed to a limited number of people with a higher risk of contracting the disease. From today, up to 1,700 gay and transgender Amsterdam residents can sign up for the program through the GGD Amsterdam site.
From today GGD health institutions will start providing the HIV prevention pill PrEP and the medical care that comes with it. The pill is intended for homosexual men, who are at higher risk of contracting HIV. The GGDs expect that thousands of men will want to use PrEP, NOS reports.
The Dutch Health Council wants the government to make HIV prevention pill Prep available to population groups that are at higher risk of being infected by the virus, such as homosexual men. According to the Health Council, the pill is medically- and cost effective and should be considered "essential care" for high risk groups, NOS reports.
The Health Council looked into Prep at the request of former Health Minister Edith Schippers.
Municipal health service GGD Amsterdam is taking part in an international scientific study in which a new HIV prevention pill will be tested on humans. The aim is to find out whether experimental drug F/TAF is safe and effective in preventing HIV infection in healthy adults. Gay men and transgender women who have sex with men who are interested in participating in this study, can register with GGD Amsterdam until March 26th, AT5 reports.
The new HIV inhibitor Prep is in high demand among gay men living in the capital. GGD Amsterdam recently announced a trial on the pill that reduces the risk of HIV infection. Only 370 men can participate in the study, but the number of applications were much higher.
GGD Amsterdam has launched a medical study on Prep - a pill that can prevent infection with HIV - among gay men and transgenders. Those interested in joining the study can apply on the GGD Amsterdam website, Soa Aids Nederland reports.